ArticleProceedings of the National Academy of Sciences of the United States of America2009
Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed.
- ORF2 of hepatitis E virus: genetic and antigenic variation across genotypes and implications for immunity, diagnostics and vaccine development.The Journal of general virology · 2026Review
- A capsid hinge region in European hepatitis E virus links mutations to genotype, virion surface properties, and environmental circulation.Applied and environmental microbiology · 2026Article
- Article
- The crucial but insufficient role of E2s domain's residues 490 and 492 in determining the host tropism of hepatitis E virus.Nature communications · 2026Article
- Immunoinformatics-based design of a multi-epitope mRNA vaccine candidate targeting the major human-infecting hepatitis E virus genotypes 1-4.Frontiers in bioinformatics · 2026Article
- Article
- Structural basis for hepatitis E virus neutralization by potent human antibodies.Science advances · 2025Article
- Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice.Nature communications · 2025Article
- RNA Helicase DDX3 Interacts with the Capsid Protein of Hepatitis E Virus and Plays a Vital Role in the Viral Replication.Pathogens (Basel, Switzerland) · 2025Article
- Epidemiology and seroprevalence of Hepatitis E Virus in Nigeria and its African context: a review and one health perspective.Le infezioni in medicina · 2025Review
- EngineeringVaccines · 2024Review
- Cell binding tropism of rat hepatitis E virus is a pivotal determinant of its zoonotic transmission to humans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- Article
- A Broad-specificity Neutralizing Nanobody against Hepatitis E Virus Capsid Protein.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Investigating the Hepatitis E Virus (HEV) Diversity in Rat Reservoirs from Northern Italy.Pathogens (Basel, Switzerland) · 2024Article
- Multiple Functions of Hepatitis E Virus ORF3.Microorganisms · 2024Review
- Pathogenesis and clinical features of severe hepatitis E virus infection.World journal of virology · 2024Review
- Hepatitis E Virus: What More Do We Need to Know?Medicina (Kaunas, Lithuania) · 2024Review
- Relevance of Tacrolimus Trough Concentration and Hepatitis E virus Genetic Changes in Kidney Transplant Recipients With Chronic Hepatitis E.Kidney international reports · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is a causative agent of acute hepatitis. The crystal structure of HEV-like particles (HEV-LP) consisting of capsid protein was determined at 3.5-A resolution. The capsid protein exhibited a quite different folding at the protruding and middle domains from the members of the families of Caliciviridae and Tombusviridae, while the shell domain shared the common folding. Tyr-288 at the 5-fold axis plays key roles in the assembly of HEV-LP, and aromatic amino acid residues are well conserved among the structurally related viruses. Mutational analyses indicated that the protruding domain is involved in the binding to the cells susceptive to HEV infection and has some neutralization epitopes. These structural and biological findings are important for understanding the molecular mechanisms of assembly and entry of HEV and also provide clues in the development of preventive and prophylactic measures for hepatitis E.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.